therapeutics
present
annual
targeted
protein
degradation
summit
watertown
globe
newswire
therapeutics
nasdaq
cccc
biopharmaceutical
company
pioneering
new
class
drugs
selectively
destroy
proteins
degradation
today
announced
present
talk
roundtable
discussion
annual
targeted
protein
degradation
summit
october
rhamy
zeid
director
target
biology
present
translational
portion
program
part
segment
titled
advancing
protein
degradation
landscape
towards
clinical
success
held
october
pm
et
talk
titled
targeted
protein
degraders
discovery
clinic
zeid
discuss
case
study
predictive
capability
platform
development
novel
selective
orally
bioavailable
degraders
protein
target
called
including
development
candidate
synovial
sarcoma
solid
tumors
stewart
fisher
chief
scientific
officer
lead
round
table
discussion
titled
challenges
world
opportunity
october
pm
et
roundtable
discuss
impact
rapid
pace
innovation
unprecedented
success
seen
every
phase
drug
discovery
need
carefully
manage
myriad
opportunities
deliver
promise
bringing
new
medicines
patients
pleased
participate
annual
targeted
protein
degradation
summit
discuss
opportunities
challenges
targeted
protein
degradation
well
present
illustrative
example
robust
capability
torpedo
platform
enables
us
select
degraders
development
confidence
said
fisher
approach
designed
optimize
overall
catalytic
efficiency
degraders
destroy
target
proteins
quickly
efficiently
possible
developing
pipeline
novel
protein
degraders
one
targets
historically
considered
undruggable
candidates
developing
potential
bring
new
treatments
patients
cancer
neurodegenerative
conditions
therapeutics
therapeutics
biopharmaceutical
company
focused
harnessing
body
natural
regulation
protein
levels
develop
novel
therapeutic
candidates
target
destroy
proteins
treatment
cancer
neurodegenerative
conditions
diseases
statements
press
release
contains
statements
therapeutics
within
meaning
private
securities
litigation
reform
act
statements
may
include
may
limited
express
implied
statements
regarding
ability
develop
potential
therapies
patients
design
potential
efficacy
therapeutic
approaches
predictive
capability
platform
development
novel
selective
orally
bioavailable
degraders
potential
timing
advancement
preclinical
studies
clinical
trials
ability
potential
successfully
manufacture
supply
product
candidates
clinical
trials
ability
replicate
results
achieved
preclinical
studies
clinical
trials
future
studies
trials
regulatory
developments
united
states
foreign
countries
statements
press
release
based
management
current
expectations
beliefs
future
events
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
set
forth
implied
statements
risks
uncertainties
include
limited
uncertainties
related
initiation
timing
conduct
studies
development
requirements
product
candidates
risk
one
product
candidates
successfully
developed
commercialized
risk
results
preclinical
studies
clinical
trials
predictive
future
results
connection
future
studies
trials
discussion
risks
uncertainties
important
factors
could
cause
actual
results
differ
contained
statements
see
section
entitled
risk
factors
therapeutics
registration
statement
form
filed
securities
exchange
commission
information
press
release
date
release
undertakes
duty
update
information
unless
required
law
